These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 36866724)

  • 21. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety.
    Chey WD; Lembo AJ; Lavins BJ; Shiff SJ; Kurtz CB; Currie MG; MacDougall JE; Jia XD; Shao JZ; Fitch DA; Baird MJ; Schneier HA; Johnston JM
    Am J Gastroenterol; 2012 Nov; 107(11):1702-12. PubMed ID: 22986437
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Randomised clinical trial: Tong-Xie-Yao-Fang granules versus placebo for patients with diarrhoea-predominant irritable bowel syndrome.
    Chen M; Tang TC; Wang Y; Shui J; Xiao XH; Lan X; Yu P; Zhang C; Wang SH; Yao J; Zheng H; Huang DQ
    Aliment Pharmacol Ther; 2018 Jul; 48(2):160-168. PubMed ID: 29856472
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fecal Microbiota Transplantation Reduces Symptoms in Some Patients With Irritable Bowel Syndrome With Predominant Abdominal Bloating: Short- and Long-term Results From a Placebo-Controlled Randomized Trial.
    Holvoet T; Joossens M; Vázquez-Castellanos JF; Christiaens E; Heyerick L; Boelens J; Verhasselt B; van Vlierberghe H; De Vos M; Raes J; De Looze D
    Gastroenterology; 2021 Jan; 160(1):145-157.e8. PubMed ID: 32681922
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Selective 5-hydroxytryptamine type 3 receptor antagonism with ondansetron as treatment for diarrhea-predominant irritable bowel syndrome: a pilot study.
    Steadman CJ; Talley NJ; Phillips SF; Zinsmeister AR
    Mayo Clin Proc; 1992 Aug; 67(8):732-8. PubMed ID: 1434911
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ramosetron for the treatment of irritable bowel syndrome with diarrhea: a systematic review and meta-analysis of randomized controlled trials.
    Qi Q; Zhang Y; Chen F; Zuo X; Li Y
    BMC Gastroenterol; 2018 Jan; 18(1):5. PubMed ID: 29310568
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study.
    Dove LS; Lembo A; Randall CW; Fogel R; Andrae D; Davenport JM; McIntyre G; Almenoff JS; Covington PS
    Gastroenterology; 2013 Aug; 145(2):329-38.e1. PubMed ID: 23583433
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Systematic review with meta-analysis: efficacy of faecal microbiota transplantation for the treatment of irritable bowel syndrome.
    Ianiro G; Eusebi LH; Black CJ; Gasbarrini A; Cammarota G; Ford AC
    Aliment Pharmacol Ther; 2019 Aug; 50(3):240-248. PubMed ID: 31136009
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The neurokinin-2 receptor antagonist ibodutant improves overall symptoms, abdominal pain and stool pattern in female patients in a phase II study of diarrhoea-predominant IBS.
    Tack J; Schumacher K; Tonini G; Scartoni S; Capriati A; Maggi CA;
    Gut; 2017 Aug; 66(8):1403-1413. PubMed ID: 27196574
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Faecal microbiota transplantation for diarrhoea-predominant irritable bowel syndrome: a double-blind, randomised, placebo-controlled trial.
    Aroniadis OC; Brandt LJ; Oneto C; Feuerstadt P; Sherman A; Wolkoff AW; Kassam Z; Sadovsky RG; Elliott RJ; Budree S; Kim M; Keller MJ
    Lancet Gastroenterol Hepatol; 2019 Sep; 4(9):675-685. PubMed ID: 31326345
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of faecal microbiota transplantation on abdominal pain, stool frequency, and stool form in patients with moderate-to-severe irritable bowel syndrome: results from a randomised, double-blind, placebo-controlled study.
    Madsen AMA; Halkjær SI; Christensen AH; Günther S; Browne PD; Kallemose T; Hansen LH; Petersen AM
    Scand J Gastroenterol; 2021 Jul; 56(7):761-769. PubMed ID: 34000958
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Positive Effect of Bimodal Release Ondansetron in Irritable Bowel Syndrome With Diarrhea: Relevance of Low-Grade Inflammation?
    Melchior C; Simrén M
    Am J Gastroenterol; 2020 Dec; 115(12):1976-1978. PubMed ID: 33079746
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of the Combination of Pinaverium Bromide 100 mg Plus Simethicone 300 mg in Abdominal Pain and Bloating in Irritable Bowel Syndrome: A Randomized, Placebo-controlled Trial.
    Schmulson MJ; Chiu-Ugalde J; Sáez-Ríos A; López-Colombo A; Mateos-Pérez GJ; Remes-Troche JM; Sobrino-Cossio S; Soto-Pérez JC; Tamayo de la Cuesta JL; Teramoto-Matsubara OT; López-Alvarenga JC
    J Clin Gastroenterol; 2020 Apr; 54(4):e30-e39. PubMed ID: 31385885
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bulking agents, antispasmodic and antidepressant medication for the treatment of irritable bowel syndrome.
    Quartero AO; Meineche-Schmidt V; Muris J; Rubin G; de Wit N
    Cochrane Database Syst Rev; 2005 Apr; (2):CD003460. PubMed ID: 15846668
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Update on the Management of Diarrhea-Predominant Irritable Bowel Syndrome: Focus on Rifaximin and Eluxadoline.
    Rivkin A; Rybalov S
    Pharmacotherapy; 2016 Mar; 36(3):300-16. PubMed ID: 26971716
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials.
    Rahimi R; Nikfar S; Abdollahi M
    Clin Ther; 2008 May; 30(5):884-901. PubMed ID: 18555935
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Optimal dose of ramosetron in female patients with irritable bowel syndrome with diarrhea: A randomized, placebo-controlled phase II study.
    Fukudo S; Matsueda K; Haruma K; Ida M; Hayase H; Akiho H; Nakashima Y; Hongo M
    Neurogastroenterol Motil; 2017 Jun; 29(6):. PubMed ID: 28205278
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Linaclotide in irritable bowel syndrome with constipation: A Phase 3 randomized trial in China and other regions.
    Yang Y; Fang J; Guo X; Dai N; Shen X; Yang Y; Sun J; Bhandari BR; Reasner DS; Cronin JA; Currie MG; Johnston JM; Zeng P; Montreewasuwat N; Chen GZ; Lim S
    J Gastroenterol Hepatol; 2018 May; 33(5):980-989. PubMed ID: 29319191
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of baseline abdominal pain and bloating on response to lubiprostone in patients with irritable bowel syndrome with constipation.
    Chang L; Chey WD; Drossman D; Losch-Beridon T; Wang M; Lichtlen P; Mareya S
    Aliment Pharmacol Ther; 2016 Nov; 44(10):1114-1122. PubMed ID: 27669680
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The efficacy of Bifidobacterium quadruple viable tablet in the treatment of diarrhea predominant irritable bowel syndrome: protocol for a randomized, double-blind, placebo-controlled, multicenter trial.
    Bai T; Zeng H; Long Y; Li X; Sun X; Lan Y; Gao L; Zhang L; Feng Z; Hou X
    Trials; 2020 Jun; 21(1):597. PubMed ID: 32605578
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.